[1]杨晓利),王峰),夏金),等.替吉奥或卡培他滨联合奥沙利铂一线治疗晚期结直肠癌效果对比分析[J].郑州大学学报(医学版),2013,(05):687.
 YANG Xiaoli),WANG Feng),XIA Jin),et al.Retrospective study on S1 plus oxaliplatin versus capecitabine plus oxaliplatin for firstline treatment of patients with advanced colorectal cancer[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2013,(05):687.
点击复制

替吉奥或卡培他滨联合奥沙利铂一线治疗晚期结直肠癌效果对比分析
分享到:

《郑州大学学报(医学版)》[ISSN:1671-6825/CN:41-1340/R]

卷:
期数:
2013年05期
页码:
687
栏目:
应用研究
出版日期:
2013-09-02

文章信息/Info

Title:
Retrospective study on S1 plus oxaliplatin versus capecitabine plus oxaliplatin for firstline treatment of patients with advanced colorectal cancer
作者:
杨晓利1)王峰2)夏金1)王亚梅2)樊青霞2)#
1)安阳市肿瘤医院内科 安阳 4550002)郑州大学第一附属医院肿瘤科 郑州 450052
Author(s):
YANG Xiaoli1)WANG Feng2)XIA Jin1)WANG Yamei2)FAN Qingxia2)
1)Department of Internal Medicine,Anyang Tumor Hospital, Anyang 4550002)Department of Oncology,the First Affiliated Hospital,Zhengzhou University,Zhengzhou 450052
关键词:
结直肠癌替吉奥卡培他滨奥沙利铂化疗
Keywords:
colorectal cancerS1 capecitabine oxaliplatin chemotherapy
分类号:
R735.3
摘要:
目的:比较替吉奥与卡培他滨分别联合奥沙利铂治疗晚期结直肠癌的效果。方法:收集75例晚期结直肠癌患者,其中采用替吉奥联合奥沙利铂方案治疗36例(替吉奥组),采用卡培他滨联合奥沙利铂治疗39例(卡培他滨组);每2个周期评价疗效及毒性,并随访2组的疾病进展时间。结果:替吉奥组和卡培他滨组的客观有效率分别为44.4%和41.0%,疾病控制率为80.5%和76.9%,中位疾病进展时间为8.6个月和8.0个月,2组以上指标相比,差异均无统计学意义(χ2=0.089、0.147、2.625,P均>0.05)。2组不良反应主要有骨髓抑制、胃肠道反应、肝功能异常、手足综合征及口腔黏膜炎等,以Ⅰ、Ⅱ级为主,但替吉奥组血小板减少发生率高于卡培他滨组(36.1% vs 15.3%,χ2=4.251,P=0.039),手足综合征发生率低于卡培他滨组(13.8% vs 35.8%,χ2=4.794,P=0.029)。结论:替吉奥联合奥沙利铂可作为晚期结直肠癌的一种新的治疗选择。
Abstract:
Aim: To compare the clinical efficacy of advanced colorectal cancer treated with S1 or capecitabine combined with oxaliplatin(LOHP). Methods:Seventyfive advanced colorectal patients were allocated into two groups: 36 patients were treated with S1 and LOHP(group S1),and 39 patients were treated with capecitabine and LOHP(group capecitabine). Every two cycles, the differences in treatment effect and adverse reaction between the two groups were compared.The time to progression was observed. Results: In group S1 and group capecitabine,the objective response rates were 44.4% and 41.0%,the disease control rates were 80.5% and 76.9%,and the median time to progress was 8.6 and 8.0 months,and there were no significant differences between the two groups(χ2=0.089,0.147,2.625,P>0.05). Adverse effects were similar in the two groups,mainly consisting of bone marrow depression,gastrointestinal reaction,dysfunction of liver and kidney,handfoot syndrome and stomatitis.Most of these side effects were of stage Ⅰ and Ⅱ. The incidence of thrombocytopenia was 36.1% in group S1, higher than that(15.3%) in group capecitabine(χ2=4.251,P=0.039). Yet,more patients in group capecitabine developed handfoot syndrome than did in group S1(35.8% vs 13.8%) (χ2=4.794,P=0.029).Conclusion: S1 plus LOHP could be regarded as a new treatment option for patients with advanced colorectal cancer.

参考文献/References:

[1]Goldberg RM,Meropol NJ,Tabernero J.Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer[J].Gastrointest Cancer Res,2009,3(5 Suppl 2):S23
[2]陈竺.全国第三次死因回顾抽样调查报告[M]. 北京:北京协和医科大学出版社,2008.
[3]高春芳,盛新华,王秀丽,等. 结直肠癌根治术后复发转移患者的预后因素分析[J]. 解放军医学杂志,2010,35(2):144
[4]Toda Y,Machida N,Boku N.The role of oral fluoropyrimidines in colorectal cancer treatmenta review[J].Gan To Kagaku Ryoho,2010,37(7):1198
[5]Porschen R, Arkenau HT, Kubicka S, et al.Phase Ⅲ study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group[J]. J Clin Oncol,2007,25(27): 4217
[6]孙燕.临床肿瘤内科手册[M].6版.北京: 人民卫生出版社,2009:271
[7]Hong YS,Park YS,Lim HY,et al. S1 plus oxaliplatin versus capecitabine plus oxaliplatin for firstline treatment of patients with metastatic colorectal cancer: a randomised, noninferiority phase 3 trial[J]. Lancet Oncol,2012,13(11):1125
[8]Yonekura K, Basaki Y, Chikahisa L, et al.UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice[J]. Clin Cancer Res,1999,5(8):2185
[9]Ooyama A, Oka T, Zhao HY, et al.Antiangiogenic effect of 5fluorouracilbased drugs against human colon cancer xenografts[J]. Cancer Lett,2008,267(1):26
[10]Harada K, Supriatno,Kawashima Y, et al.S1 inhibits tumorigenicity and angiogenesis of human oral squamous cell carcinoma cells by suppressing expression of phosphorylated Akt, vascular endothelial growth factor and fibroblast growth factor2[J]. Int J Oncol,2007,30(2): 365
[11]Cassidy J, Tabernero J, Twelves C,et al.XELOX (capecitabine plus oxaliplatin): active firstline therapy for patients with metastatic colorectal cancer[J].J Clin Oncol, 2004, 22(11):2084
[12]Yaman E,Uner A,Er O,et al. Capecitabine plus oxaliplatin( xelox) in the treatment of chemotherapynaive patients with metastatic colorectal cancer[J].Med Oncol,2007,24(4):431
[13]耿丽,樊青霞,张浩.希罗达联合草酸铂治疗转移性结直肠癌18例疗效观察[J].郑州大学学报:医学版,2004,39(4):705
[14]Nekatsuka M,Saito H,Sakamoto K,et al.Efficacy of combination chemotherapy using oral fluoropyrimidine S1 with oxaliplatin (SOX) against colorectal cancer in vivo[J].Anticancer Res,2012,32(7):2807

相似文献/References:

[1]冯静)△,陈小兵),赵明耀),等.合并肝转移的结直肠癌组织中VEGF和Survivin蛋白的表达*[J].郑州大学学报(医学版),2010,(02):207.
 FENG Jing),CHEN Xiaobing),ZHAO Mingyao),et al.Expression of VEGF and Survivin protein in colorectal carcinoma tissue with liver metastasis[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2010,(05):207.
[2]刘天舟△,王瑞.结直肠癌患者血清中IGF1、MMP7和IGFBP3水平分析[J].郑州大学学报(医学版),2011,(05):726.
 LIU Tianzhou,WANG Rui.Levels of serum IGFI,MMP7 and IGFBP3 in colorectal cancer patients[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2011,(05):726.
[3]袁娜娜,卢高峰,唐芙爱#.人结直肠癌组织中肿瘤相关巨噬细胞的检测[J].郑州大学学报(医学版),2013,(01):106.
 YUAN Nana,LU Gaofeng,TANG Fuai.Detection of tumorassociated macrophages in colorectal cancer tissue[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2013,(05):106.
[4]彭方慧,王峰,何炜,等.替吉奥与5氟尿嘧啶联合奈达铂治疗晚期食管癌的疗效比较*[J].郑州大学学报(医学版),2013,(02):160.
 PENG Fanghui,WANG Feng,HE Wei,et al.Comparison of clinical efficacy of advanced esophageal cancer treated with S1 and 5fluorouracil combined with nedaplatin[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2013,(05):160.
[5]季润元)△,史恩溢),王永实),等.结直肠癌组织中运动相关蛋白1/CD9和ME491/CD63的表达*[J].郑州大学学报(医学版),2012,(06):782.
 JI Runyuan,SHI Enyi,WANG Yongshi,et al.Expressions of MRP1/CD9 and ME491/CD63 in colorectal carcinoma tissue[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2012,(05):782.
[6]王朝杰,马宁,周云#.结直肠癌组织和结肠癌细胞中miR31的表达及功能*[J].郑州大学学报(医学版),2013,(05):625.
 WANG Chaojie,MA Ning,ZHOU Yun.Expression and function of miR31 in colorectal cancer tissue and HCT116 cells[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2013,(05):625.
[7]王瑞华),谢建国)#,付强),等.结直肠癌组织中Ang2、Tie2 mRNA的表达及Kras基因突变的检测*[J].郑州大学学报(医学版),2013,(05):629.
 WANG Ruihua),XIE Jianguo),FU Qiang),et al.Expression of Ang2,Tie2 mRNA and Kras gene mutation in human colorectal cancer tissue[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2013,(05):629.
[8]李帅,周志刚#,高剑波,等.CT引导下组织间植入125I粒子联合替吉奥治疗老年胰腺癌疗效分析[J].郑州大学学报(医学版),2015,(02):270.
 LI Shuai,ZHOU Zhigang,GAO Jianbo,et al.Efficacy of CTguided implantation of 125I seeds combined with S1 in treatment of pancreatic cancer in elderly patients[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2015,(05):270.
[9]吴新新,马杰,任鹏飞,等.结直肠癌KRAS、NRAS和BRAF 基因突变与病理特征、吸烟和饮酒之间的相关性[J].郑州大学学报(医学版),2016,(01):39.
 WU Xinxin,MA Jie,REN Pengfei,et al.Relationship between KRAS,NRAS and BRAF gene mutation and pathological features,smoking and drinking of patients with colorectal cancer[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2016,(05):39.
[10]付 强,张金岱,谢建国.上调睾丸特异性Y样蛋白5的表达对LoVo细胞侵袭、迁移及STAT3蛋白表达的影响[J].郑州大学学报(医学版),2019,(06):845.[doi:10.13705/j.issn.1671-6825.2018.08.012]
 FU Qiang,ZHANG Jindai,XIE Jianguo.Effects of up-regulating TSPYL5 on invasion and metastasis of LoVo cells and STAT3 protein[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2019,(05):845.[doi:10.13705/j.issn.1671-6825.2018.08.012]

更新日期/Last Update: 2013-09-01